Front Page VSPN Message Boards Chat Library Continual Education Search MyVSPN - Coming Soon Help Frequently Asked Questions Send us Feedback! Go to VIN Industry Partners Go to VetQuest Go to Veterinary Partner Go to Y2Spay
 
Menu bar   Go to the VIN.com Portal
 

ABSTRACT OF THE WEEK

Research in veterinary science
Volume 160 | Issue 0 (July 2023)

Dimethyl sulfoxide favors the emetic efficacy of lycorine in beagle dogs - a novel strategy for the treatment of poisoning.

Res Vet Sci. July 2023;160(0):11 - 17.
Ralf Regenthal1, Getu Abraham2
1 Division of Clinical Pharmacology, Rudolf Boehm Institute for Pharmacology and Toxicology, Medical Faculty, University of Leipzig, Härtelstrasse 16-18, 04107 Leipzig, Germany. Electronic address: ralf.regenthal@medizin.uni-leipzig.de.; 2 Institute of Pharmacology, Pharmacy and Toxicology, Faculty of Veterinary Medicine, University of Leipzig, An den Tierkliniken 15, 04103 Leipzig, Germany.
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Abstract

Poisoning in small animals represents an ongoing hazard and therapeutic problem in veterinary medicine. Therapeutic induction of emesis in time enables a fast elimination of a toxic compound resulting in a shortened course of poisoning and a higher safety level thereafter, which decisively improves prognosis and treatment. Lycorine is a reliable emetic drug in beagle dogs without serious side effects thought to be more beneficial in tolerability and efficacy than the rarely used apomorphine. Therefore, this study investigates efficacy and tolerability of differently composed potential drug formulations of lycorine hydrochloride for s.c. administration in dogs as an emetic principle. By emesis response analysis four dimethyl sulfoxide (DMSO)-based active pharmaceutical ingredient (API) formulations were favored. Two of them (F5 and F6) qualified for further drug development. Both formulations ensure a safe pharmacologically induced emesis within about 30 min after injection, suitable for use as an in time decontaminant in acute poisoning of dogs. DMSO-based formulations were well tolerated and offer a novel promising strategy for treatment of poisoning.

Keywords
Dog; Drug formulation; Emetic drug; Lycorine; Poisoning;

Article Tools:
   Medline
   Email to me

Archives Highlights:
The 4 prokinetic drugs metoclopramide, cisapride, pyridostigmine, and capromorelin do not increase fecal output or food intake in healthy New Zealand rabbits (Oryctolagus cuniculus).
Every day, rabbits produced a median of 75 g (range, 9 to 145 g) of feces, 226 fecal pellets (range, 12 to 412 pellets), and 151 mL (range, 5 to 420 mL) of urine. Metoclopramide, cisapride, pyridostigmine, and capromorelin had no effect on fecal production (both weight and number of pellets), food intake, urine production, or water intake compared to placebo at 24, 48, or 72 hours after administration.
Cryptorchidism in dogs and cats presented for elective gonadectomy: A descriptive cohort study of 306 animals treated between 2018 and 2023.
5,476 dogs and 11,559 cats were presented to the same facility for elective surgical castration, suggesting a cryptorchid incidence of 3.21 % for dogs and 1.12 % for cats. Cryptorchid testes were more commonly observed in the inguinal area than in the abdomen, and were more frequently located unilaterally on the right side in both dogs and cats.
Guide for nonswine practitioners to enhance swine disease diagnoses.
This review aims to help clinicians across the country that may not have an in-depth experience in swine medicine become more familiar with both common and novel pathogens, formulate a differential diagnosis based on the age of the animals and affected system (eg, respiratory, systemic, nervous, and enteric), select proper samples and laboratory testing, and interpret laboratory data to achieve a disease diagnosis in porcine patients.
Effects of intranasal maropitant on clinical signs of naturally acquired upper respiratory disease in shelter cats.
There was no significant difference in clinical improvement score between the maropitant treatment and control groups for conjunctivitis, blepharospasm, ocular discharge, nasal discharge, or total disease severity after 7 days.
Duration of efficacy and effect of implant location in adult queens treated with a 9.4 mg deslorelin subcutaneous implant.
The average duration of action of the 9.4 mg deslorelin implant was 790 ± 155 days (range 525-1140 days) with no significant difference in duration or efficacy depending on implantation sites. The 9.4 mg deslorelin implant causes pharmacological sterilization for about 2 years in female cats, is fully reversible, and caused no clinically relevant side effects when administered at both interscapular and periumbilical sites.

Back Print Save Bookmark in my Browser Email this article to me. Top of Page. VSPN AOW : Dimethyl sulfoxide favors...
Contact Us